The M371-Test offers you unrivalled diagnostic accuracy and enables a ground-breaking approach to the treatment of testicular cancer. A landmark study has demonstrated the efficacy of the M371-Test from mir|detect in the detection of recurrences of germ cell tumours of the testis.
Early detection of recurrence is crucial in the follow-up of patients with testicular germ cell tumours. In a recently published study, serum levels of miR-371a-3p were analysed in 258 patients with the M371-Test from mir|detect monitored. During the follow-up period, 39 relapses occurred. Elevated levels of miRNA were detected in all of these cases, which corresponds to a sensitivity and specificity of 100 % and 96.3 % respectively. This means that miR-371a-3p clearly outperforms the classic serum markers.
These results emphasise the suitability of the M371-Test from mir|detect for the detection of recurrences, and the test thus represents a significant advance in the follow-up care of testicular cancer patients. The paper was published in Clinical Cancer Research and is now available online: https://doi.org/10.1158/1078-0432.ccr-23-0730